2020
Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database
Punekar S, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. American Journal Of Clinical Oncology 2020, 43: 846-849. PMID: 32910023, DOI: 10.1097/coc.0000000000000761.Peer-Reviewed Original ResearchConceptsG3 neuroendocrine tumorsColorectal neuroendocrine tumorsNeuroendocrine tumorsOverall survivalUnmarried patientsCox proportional hazards modelEnd Results (SEER) databaseGastrointestinal neuroendocrine tumorsPredictors of survivalPrognosis of patientsNational registry studyProportional hazards modelOlder patientsRegistry studySEER databaseWorse survivalMedian ageSurveillance EpidemiologyBlack patientsResults databaseTumor characteristicsHazards modelPatientsSmall studyLogistic regression
2019
Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors.
Punekar S, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors. Journal Of Clinical Oncology 2019, 37: e15696-e15696. DOI: 10.1200/jco.2019.37.15_suppl.e15696.Peer-Reviewed Original ResearchOverall survivalNeuroendocrine tumorsCarcinoid tumorsSmall cell neuroendocrine tumorsCox proportional hazards modelColorectal carcinoid tumorsEnd Results (SEER) databaseDemographics of patientsPredictors of survivalColorectal neuroendocrine tumorsNew pathologic entityProportional hazards modelPatient demographicsMedian ageSurveillance EpidemiologyBlack patientsResults databaseTumor characteristicsPathologic entityTumor gradeGI tractHazards modelPatientsSmall studyTumorsTreatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
BECKER D, IYENGAR A, PUNEKAR S, NG J, ZAMAN A, LOEB S, BECKER K, MAKAROV D. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer Research 2019, 39: 2467-2473. PMID: 31092441, DOI: 10.21873/anticanres.13366.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAbi/enzaCastration-resistant prostate cancerPSA progressionEnd of lifeProstate cancerVeterans AffairsOlder patientsBlack patientsClinical benefitClinical endpointsHospice servicesNational guidelinesPatientsEnza treatmentAdditional studiesProgressionENZAAbirateroneRegression analysisCancerTreatmentABIEnzalutamideEndpoint